Article Per Year (5 Year)
p-Index From 2020 - 2025
0.444
P-Index
This Author published in this journals
All Journal Trends in Infection and Global Health
Adejuyigbe, Zacchaeus
Unknown Affiliation
Biochemistry, Genetics & Molecular Biology Health Professions Immunology & microbiology Medicine & Pharmacology Public Health

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search
Journal : Trends in Infection and Global Health

 1 
Exploring the co-infection of tuberculosis and hepatitis B virus in people living with HIV: Implications for diagnosis and treatment Dansura, Mangpin L.; Dangana, Amos; Samuel, Bwede E.; Gagari, Villeng F.; Miri, Nanpon; Gyang, Nyiri M.; Adejuyigbe, Zacchaeus; Ugwu, Chinwe N.; Nanbol, Helen D.; Uzoebo, Nkiruka
Trends in Infection and Global Health Vol 4, No 2 (2024): December 2024
Publisher : School of Medicine, Universitas Syiah Kuala

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.24815/tigh.v4i2.40662

Abstract

Hepatitis B virus (HBV) and tuberculosis (TB) infections are common causes of liver cirrhosis and hepatocellular carcinoma. First-line anti-TB medications are known to cause drug-induced liver injury (DILI). This study aimed to investigate whether HBV and TB co-infection increase susceptibility to liver failure and poor outcomes during anti-TB treatment in HIV-positive patients. HBV infection was detected using the ELISA method, while TB infection was confirmed through Lowenstein-Jensen (LJ) medium culture. The severity and incidence of liver failure and mortality were compared, and risk factors influencing clinical outcomes were identified. Patients were categorized as new TB cases, relapse TB cases, or defaulters. Among the total cases, 64.5% were classified as new, 18% as relapse, and 17.5% as defaulters TB cases. The prevalence of HBV infection among new, relapse, and defaulter cases was 11.5%, 4.8%, and 1.6%, respectively. In terms of TB classification, the prevalence of HBV infection among patients with pulmonary TB and extrapulmonary TB was 10.6% and 7.1%, respectively, with no cases recorded in the defaulter category. The prevalence of triple infection (HIV-TB-HBV) was found to be 13.3% in new TB cases and 3.3% in relapse TB cases. Patients undergoing anti-TB therapy with chronic HBV co-infection were more susceptible to liver failure and had poorer treatment outcomes. Regular monitoring of liver function is essential, and anti-HBV therapy should be considered for patients with high viral loads before initiating anti-TB treatment.
Co-infection of tuberculosis and hepatitis B virus in HIV patients: Implications for diagnosis and treatment Dansura, Mangpin L.; Dangana, Amos; Samuel, Bwede E.; Gagari, Villeng F.; Miri, Nanpon; Gyang, Nyiri M.; Adejuyigbe, Zacchaeus; Ugwu, Chinwe N.; Nanbol, Helen D.; Uzoebo, Nkiruka
Trends in Infection and Global Health Vol 5, No 1 (2025): June 2025
Publisher : School of Medicine, Universitas Syiah Kuala

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.24815/tigh.v5i1.44389

Abstract

Hepatitis B virus (HBV) and tuberculosis (TB) infections are common causes of liver cirrhosis and hepatocellular carcinoma. First-line anti-TB medications are known to cause drug-induced liver injury (DILI). The aim of this study was to investigate whether HBV and TB co-infection increases susceptibility to liver failure and poor outcomes during anti-TB treatment in HIV-positive patients. HBV infection was detected using the enzyme-linked immunosorbent assay (ELISA) method, while TB infection was confirmed through Lowenstein-Jensen (LJ) medium culture. The severity and incidence of liver failure and mortality were compared, and risk factors influencing clinical outcomes were identified. Patients were categorized as new TB cases, relapse TB cases, or defaulters. Among the total cases, 64.5% were classified as new, 18% as relapse, and 17.5% as defaulters of TB cases. The prevalence of HBV infection among new, relapse, and defaulter cases was 11.5%, 4.8%, and 1.6%, respectively. In terms of TB classification, the prevalence of HBV infection among patients with pulmonary TB and extrapulmonary TB was 10.6% and 7.1%, respectively, with no cases recorded in the defaulter category. The prevalence of triple infection (HIV-TB-HBV) was found to be 13.3% in new TB cases and 3.3% in relapse TB cases. Patients undergoing anti-TB therapy with chronic HBV co-infection were more susceptible to liver failure and had poorer treatment outcomes. Regular monitoring of liver function is essential, and anti-HBV therapy should be considered for patients with high viral loads before initiating anti-TB treatment.
Co-Authors Dangana, Amos Dansura, Mangpin L. Gagari, Villeng F. Gyang, Nyiri M. Miri, Nanpon Nanbol, Helen D. Samuel, Bwede E. Ugwu, Chinwe N. Uzoebo, Nkiruka